



PRESENT

WP1	Inez Germeys Silke Apers	
WP2	Simon Krause	
WP3	Thomas Ganslandt	
WP4	Georgia Koppe	
WP5	/	
WP6	/	
WP7	Matthias Schwannauer Anita Schick Ulrich Reininghaus	Joanne Beames Michal Hajduk
WP8	Jeroen Weermeijer	

1. General Management

- a. Please follow-up on the action points that were made at the GA
 - i. Workshops are being scheduled
- b. Practice sessions for the evaluation went well
- c. Questionnaire on innovation radar to be submitted on 14/06/24
 - i. Evaluation 19/6: Describe what we have developed and trialed so far (DMMH) and what we want to do with future developments (what is needed to bring it into market, where do we need further funding, ...) - Jeroen will present on this during the evaluation
 - Which innovations should be included? Focus on DMMH or also include other innovations that still have to be developed further (e.g. therapyBuilder, MDR process, guidance on how to move towards EC mark, ...) -> focus on DMMH as innovation output
 - Simon will check-in with Jörg: ask him to have a look at this and make a back-up slide on differences DMMH & TherapyDesigner, so that we can show this if any confusion would arise during the evaluation
 - Silke will send in the questionnaire

2. WP2

- a. No updates

3. WP3

- b. Leuven PhD-students:
 - Rafaël needs patient, clinician and DMMH-data (compliance) from intervention period for paper (doesn't have to be published yet).
 - Lena needs Phase 1 quantitative data.
- c. Thomas will follow-up with Maria to check if Phase 1 dataset is final/cleaned.
- d. Will work on conversion script by September (when recruitment and intervention periods have ended for all participants/data is collected).
- e. MaganaMed data will only be available after data set is closed (cfr. WP7)

4. WP4

- f. No updates

5. WP5: /

6. WP6: /

7. WP7

- g. **Database lock is technically feasible (cfr. Slides presented by Uli)**
 - **First lock of baseline data**
 1. Workshops have to be scheduled over the summer
 2. All PI's will have to sign the forms
 3. Stefanie Engelhardt can then do her first check of the data in July. If any errors occur, the teams will have to be contacted to correct them by end of August so that Stefanie can check data again in September.
 4. By the end of September, we will have DMMH and baseline data available for analyses
 - Lock and release of t1, t2 and t3 in April 25
- h. Corrections and changes performed to data would ideally have to be part of the audit trails (MaganaMed allows for corrections, but certain checks will have to be performed externally). --> Thomas and Uli will meet up to go over what checks are necessary
- i. ESM data: data lock is not possible (no technical solution)
- j. We will have to adjust this timeline in our pre-registration on the OSF
- k. Data access for analyses on adverse events is okay

8. WP8

- l. Approve abstract 19 (request via DROPS)? -> OK
- m. Abstract 20 was more a call for contribution, not an abstract

9. AOB

- n. Aim to submit opinion piece next Thursday
- o. Next meeting on July 18th